Bristol-Myers Squibb (NYSE:BMY) Trading Down 0.1%

Bristol-Myers Squibb (NYSE:BMY)’s share price dropped 0.1% during trading on Thursday . The company traded as low as $47.31 and last traded at $47.53. Approximately 2,297,031 shares traded hands during mid-day trading, a decline of 86% from the average daily volume of 15,904,463 shares. The stock had previously closed at $47.56.

Wall Street Analyst Weigh In

BMY has been the subject of a number of recent research reports. Deutsche Bank Aktiengesellschaft reduced their target price on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating for the company in a report on Tuesday, July 23rd. Wells Fargo & Company upped their target price on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research report on Thursday, April 18th. Cantor Fitzgerald restated a “neutral” rating and issued a $45.00 price objective on shares of Bristol-Myers Squibb in a research report on Monday, July 22nd. StockNews.com upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Monday. Finally, BMO Capital Markets lowered their price objective on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research report on Friday, April 26th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $55.79.

Bristol-Myers Squibb Trading Up 1.3 %

The company has a 50 day moving average of $42.11 and a 200 day moving average of $46.75. The company has a debt-to-equity ratio of 2.86, a quick ratio of 0.99 and a current ratio of 1.16. The stock has a market capitalization of $97.66 billion, a price-to-earnings ratio of -15.53, a P/E/G ratio of 12.58 and a beta of 0.44.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.64 by $0.43. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. The business had revenue of $12.20 billion during the quarter, compared to the consensus estimate of $11.54 billion. During the same period last year, the company earned $1.75 EPS. The company’s revenue for the quarter was up 8.7% on a year-over-year basis. On average, research analysts predict that Bristol-Myers Squibb will post 0.78 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Friday, July 5th will be paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.98%. The ex-dividend date of this dividend is Friday, July 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -77.42%.

Institutional Trading of Bristol-Myers Squibb

Hedge funds and other institutional investors have recently modified their holdings of the stock. Northwest Financial Advisors purchased a new position in shares of Bristol-Myers Squibb during the 4th quarter worth $27,000. ESL Trust Services LLC purchased a new position in shares of Bristol-Myers Squibb during the 1st quarter worth $27,000. Accordant Advisory Group Inc purchased a new position in shares of Bristol-Myers Squibb during the 1st quarter worth $31,000. Pacific Capital Wealth Advisors Inc. purchased a new position in Bristol-Myers Squibb during the 4th quarter valued at about $34,000. Finally, MFA Wealth Advisors LLC purchased a new position in Bristol-Myers Squibb during the 2nd quarter valued at about $39,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.